NEW YORK – Metsera, a clinical-stage biopharmaceutical firm specializing on next-generation therapies for obesity and cardiometabolic disorders, has reached a final agreement to be acquired by Pfizer Inc (PFE). The contract is projected to be worth $4.9 billion up front, with an extra $2.4 billion in future payments contingent on performance milestones, for a total estimated value of $7.3 billion.
The acquisition is a calculated attempt by Pfizer to get back into the competitive weight-loss medication industry, which has been dominated by competitors like Novo Nordisk and Eli Lilly. Danuglipron, Pfizer’s own oral weight-loss medication, was terminated earlier this year because of safety and tolerability issues.
Metsera’s portfolio of unique injectable and oral incretin and amylin treatment prospects were acquired by Pfizer. The pipeline consists of:
- MET-097i is a Phase 2 injectable GLP-1 receptor agonist that is available once a week and once a month.
- A monthly amylin analog candidate called MET-233i is being studied both alone and in conjunction with MET-097i.
- Clinical studies for two oral GLP-1 receptor agonists are anticipated to start shortly.
Obesity is a large and growing space with over 200 health conditions associated with it. The proposed acquisition of Metsera aligns with our focus on directing our investments to the most impactful opportunities and propels Pfizer into this key therapeutic area,
We are excited to apply our deep cardiometabolic experience and manufacturing and commercial infrastructure to accelerate a portfolio that includes potential best-in-class injectables, with clinical data differentiated by efficacy, tolerability and durability supporting monthly dosing, with the aim to address the ongoing unmet needs associated with obesity and related diseases.
Albert Bourla
GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer
GSK’s risvutatug rezetecan has officially secured Orphan Drug Designation from Japan’s MHLW for the treatment of small-cell lung cancer (SCLC). Supported by durable response data […]
Pfizer paid $47.50 per share in cash after close, giving Metsera stockholders a substantial premium. A contingent value right (CVR) offers an extra $22.50 per share in the event that specific clinical and regulatory milestones are reached, such as the FDA approving important assets and the commencement of a Phase 3 trial.
Last Modified:
Graduated from the University of Kerala with B.Sc. Botany and Biotechnology. Attained Post-Graduation in Biotechnology from the Kerala University of Fisheries and Ocean Science (KUFOS) with the third rank. Conducted various seminars and attended major Science conferences. Done 6 months of internship in ICMR – National Institute of Nutrition, Hyderabad. 5 years of tutoring experience.
